British HIV Association guidelines on the management of opportunistic infection in people living with HIV:
The clinical management of Candidiasis 2019
Advances in the treatment of HIV infection with antiretroviral therapy have led to dramatic reductions in opportunistic infections and death. However, late presentation of HIV remains a problem and is a significant contributory cause of death in people living with HIV in the UK. Individuals who are lost to follow-up or who are not able to adhere to antiretroviral therapy long term can also present with opportunistic infection. In addition, an increasing number of people living with HIV are receiving immunosuppressive medications that can alter susceptibility to opportunistic infection for reasons other than direct HIV replication.
The aim of the opportunistic infection guidelines is to help physicians investigate and manage people living with HIV with, or suspected of having, an opportunistic infection. They are primarily intended to guide practice in the UK and related healthcare systems.
The previous BHIVA/BIA guidelines for the treatment of opportunistic infection 2011 are being updated chapter by chapter using the same general methodology; this chapter provides guidance on the clinical management of candidiasis.
Public consultation comments
The comments received during the public consultation can be found below. All comments were reviewed and discussed, and the guidelines amended where appropriate.
Declaration of interests
Writing group members
DH Dockrell, University of Edinburgh and Regional Infectious Diseases Unit, NHS Lothian Infection Service, Edinburgh, UK
D O’Shea, University of Edinburgh and Regional Infectious Diseases Unit, NHS Lothian Infection Service, Edinburgh, UK
JD Cartledge, Mortimer Market Centre, London, UK
AR Freedman, Cardiff University School of Medicine, Cardiff, UK